{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"pt-141-skin","title":"PT-141 for Skin: Evidence Review of Effects and Observations","body":"## What's breaking down\n\nSkin tissue can face layers of degeneration where repair pathways lag behind daily wear, UV exposure, inflammation, or hormonal shifts. Pigment cells (melanocytes) may over- or under-respond, leading to uneven tone, spots, or loss of even coloration. Vascular and nerve signals in the skin also influence flushing or localized reactions. When breakdown outpaces natural repair, visible changes persist. PT-141 is discussed in this context because it engages melanocortin pathways that touch both central signaling and peripheral tissue responses.\n\n## Why PT-141 might help you\n\n1. **Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\n\nThe compound acts on melanocortin receptors including MC1R in skin cells. This interaction is studied for its role in melanocyte activity, which relates to pigment production and local tissue responses. If skin pigmentation or repair balance is your concern, the pathway offers a direct mechanistic link rather than symptom suppression alone.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **PT-141** → sexual / CNS arousal\n\n## What the evidence actually shows\n\nHuman data come from clinical trials of bremelanotide for hypoactive sexual desire disorder. In those studies, focal hyperpigmentation occurred in about 1% of participants using up to 8 doses per month (human|source from trial reports). Daily use for 8 days led to focal hyperpigmentation in 38% of a smaller group, with additional changes after another 8 days (human). Flushing affected around 20% of users (human). No dedicated human trials examined PT-141 as a primary skin treatment.\n\nPreclinical work on related melanocortin agonists shows MC1R activation increases pigmentation in cell and animal models (preclinical). Rat and cell studies on melanocortin pathways confirm effects on melanocytes but do not translate directly to therapeutic skin repair in humans.\n\n## What scientists say\n\nReviews note that bremelanotide engages MC1R and MC4R; MC1R activity links to melanocyte stimulation and pigmentation changes (mechanistic). Authors describe hyperpigmentation as an uncommon adverse reaction, more noticeable with frequent dosing or darker baseline skin (human data summary). No claims appear for intentional skin regeneration benefits.\n\n## What people say on Reddit\n\nUsers report noticing darker patches on the face or temples within a week of starting PT-141 (anecdotal). Some describe new moles or freckling after doses (anecdotal). Others report no visible skin changes despite regular use (anecdotal). Threads discuss whether changes are permanent or fade after stopping (anecdotal).\n\n## What people say on X\n\nPosts echo similar observations of temporary darkening or flushing after injections (anecdotal). A few mention gum or breast area changes with repeated use (anecdotal). Most comments tie effects to dose frequency rather than skin improvement goals (anecdotal).\n\n## What we do not know\n\nNo human trials test PT-141 specifically for skin repair, pigmentation disorders, or wound healing. Long-term effects on skin beyond trial durations remain unstudied in controlled settings. Individual variability in MC1R response is noted but not quantified for skin outcomes. Animal data on tissue repair pathways exist for related compounds yet lack direct mapping to this peptide in skin conditions.\n\n## Safety and limits\n\nHuman trial data list nausea, flushing, and injection-site reactions as common (human). Hyperpigmentation risk rises with daily or frequent use (human). Blood pressure increases appear in some users (human). Evidence does not support unsupervised use; all observations come from approved or research contexts only.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/pt-141-skin/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Focal hyperpigmentation occurred in about 1% of bremelanotide trial participants using up to 8 doses per month.","section":"What the evidence actually shows","tier":"human","source_ids":["s0"],"source_status":"sourced","why_material":"Documents the rate of skin pigmentation side effect in controlled human studies.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:08:05.576Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Daily use for 8 days produced focal hyperpigmentation in 38% of participants in one clinical study.","section":"What the evidence actually shows","tier":"human","source_ids":["s13"],"source_status":"sourced","why_material":"Provides frequency data under higher exposure conditions.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:08:05.576Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Bremelanotide activates MC1R, which stimulates melanocytes and can increase pigmentation.","section":"Why PT-141 might help you","tier":"mechanistic","source_ids":["s0"],"source_status":"sourced","why_material":"Explains the receptor-level link to skin effects.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:08:05.576Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Flushing affected approximately 20% of users in trials.","section":"What the evidence actually shows","tier":"human","source_ids":["s0"],"source_status":"sourced","why_material":"Common vascular skin response observed in humans.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:08:05.576Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Reddit users describe facial darkening or new moles after PT-141 use.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s14"],"source_status":"sourced","why_material":"Captures self-reported skin observations outside trials.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:08:05.576Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s0","type":"pubmed","url":"https://www.ncbi.nlm.nih.gov/books/NBK573221/","title":"Bremelanotide - LiverTox® - NCBI Bookshelf","quote":"In the skin, melanocortin receptors activate melanocytes and cause increase in pigmentation. ... Uncommon adverse reactions have included ... local hyperpigmentation.","summary":"Reviews mechanism and side effects including pigmentation changes from clinical data.","claim_ids":["c1","c3","c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:08:04.174Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"7363cbda5856b5d482080090cdfbe524ae38872a5ddca08b7b2cac94e910de68"},{"id":"s13","type":"medical","url":"https://www.drugs.com/sfx/bremelanotide-side-effects.html","title":"Bremelanotide Side Effects","quote":"In another clinical study, 38% of patients developed focal hyperpigmentation after receiving this drug daily for 8 days.","summary":"Details hyperpigmentation rates under daily dosing in studies.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:08:04.174Z","link_status":"http_403","quote_status":"unverified","prev":"7363cbda5856b5d482080090cdfbe524ae38872a5ddca08b7b2cac94e910de68","hash":"1604e7007ac637721948fb192e99046539faa35dae958d7cd4965402000acca9"},{"id":"s14","type":"reddit","url":"https://www.reddit.com/r/Peptides/comments/1c0ht3j/pt141_whats_the_likelihood_of_permanent_skin/","title":"PT-141 What's the likelihood of permanent skin darkening?","quote":"I started PT-141 2 weeks ago and I noticed my skin getting darker in about a week and now I have hyperpigmentation spots around my temples","summary":"User reports of skin darkening after PT-141 initiation.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:08:04.174Z","link_status":"ok","quote_status":"unverified","prev":"1604e7007ac637721948fb192e99046539faa35dae958d7cd4965402000acca9","hash":"1566de26be5b19d24a47d8347a7bea223712bf3acf90302e070c32f5387c5b4a"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T01:08:05.963Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"PT-141 for Skin: Evidence Review of Effects and Observations","register":"source_ledger","body":"## What's breaking down\n\nSkin tissue can face layers of degeneration where repair pathways lag behind daily wear, UV exposure, inflammation, or hormonal shifts. Pigment cells (melanocytes) may over- or under-respond, leading to uneven tone, spots, or loss of even coloration. Vascular and nerve signals in the skin also influence flushing or localized reactions. When breakdown outpaces natural repair, visible changes persist. PT-141 is discussed in this context because it engages melanocortin pathways that touch both central signaling and peripheral tissue responses.\n\n## Why PT-141 might help you\n\n1. **Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\n\nThe compound acts on melanocortin receptors including MC1R in skin cells. This interaction is studied for its role in melanocyte activity, which relates to pigment production and local tissue responses. If skin pigmentation or repair balance is your concern, the pathway offers a direct mechanistic link rather than symptom suppression alone.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **PT-141** → sexual / CNS arousal\n\n## What the evidence actually shows\n\nHuman data come from clinical trials of bremelanotide for hypoactive sexual desire disorder. In those studies, focal hyperpigmentation occurred in about 1% of participants using up to 8 doses per month (human|source from trial reports). Daily use for 8 days led to focal hyperpigmentation in 38% of a smaller group, with additional changes after another 8 days (human). Flushing affected around 20% of users (human). No dedicated human trials examined PT-141 as a primary skin treatment.\n\nPreclinical work on related melanocortin agonists shows MC1R activation increases pigmentation in cell and animal models (preclinical). Rat and cell studies on melanocortin pathways confirm effects on melanocytes but do not translate directly to therapeutic skin repair in humans.\n\n## What scientists say\n\nReviews note that bremelanotide engages MC1R and MC4R; MC1R activity links to melanocyte stimulation and pigmentation changes (mechanistic). Authors describe hyperpigmentation as an uncommon adverse reaction, more noticeable with frequent dosing or darker baseline skin (human data summary). No claims appear for intentional skin regeneration benefits.\n\n## What people say on Reddit\n\nUsers report noticing darker patches on the face or temples within a week of starting PT-141 (anecdotal). Some describe new moles or freckling after doses (anecdotal). Others report no visible skin changes despite regular use (anecdotal). Threads discuss whether changes are permanent or fade after stopping (anecdotal).\n\n## What people say on X\n\nPosts echo similar observations of temporary darkening or flushing after injections (anecdotal). A few mention gum or breast area changes with repeated use (anecdotal). Most comments tie effects to dose frequency rather than skin improvement goals (anecdotal).\n\n## What we do not know\n\nNo human trials test PT-141 specifically for skin repair, pigmentation disorders, or wound healing. Long-term effects on skin beyond trial durations remain unstudied in controlled settings. Individual variability in MC1R response is noted but not quantified for skin outcomes. Animal data on tissue repair pathways exist for related compounds yet lack direct mapping to this peptide in skin conditions.\n\n## Safety and limits\n\nHuman trial data list nausea, flushing, and injection-site reactions as common (human). Hyperpigmentation risk rises with daily or frequent use (human). Blood pressure increases appear in some users (human). Evidence does not support unsupervised use; all observations come from approved or research contexts only.","claims":[{"id":"c1","text":"Focal hyperpigmentation occurred in about 1% of bremelanotide trial participants using up to 8 doses per month.","section":"What the evidence actually shows","tier":"human","source_ids":[],"source_status":"unsourced","why_material":"Documents the rate of skin pigmentation side effect in controlled human studies.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:08:05.576Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Daily use for 8 days produced focal hyperpigmentation in 38% of participants in one clinical study.","section":"What the evidence actually shows","tier":"human","source_ids":["s13"],"source_status":"sourced","why_material":"Provides frequency data under higher exposure conditions.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:08:05.576Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Bremelanotide activates MC1R, which stimulates melanocytes and can increase pigmentation.","section":"Why PT-141 might help you","tier":"mechanistic","source_ids":["s0"],"source_status":"sourced","why_material":"Explains the receptor-level link to skin effects.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:08:05.576Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Flushing affected approximately 20% of users in trials.","section":"What the evidence actually shows","tier":"human","source_ids":["s0"],"source_status":"sourced","why_material":"Common vascular skin response observed in humans.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:08:05.576Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Reddit users describe facial darkening or new moles after PT-141 use.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s14"],"source_status":"sourced","why_material":"Captures self-reported skin observations outside trials.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:08:05.576Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s0","type":"pubmed","url":"https://www.ncbi.nlm.nih.gov/books/NBK573221/","title":"Bremelanotide - LiverTox® - NCBI Bookshelf","quote":"In the skin, melanocortin receptors activate melanocytes and cause increase in pigmentation. ... Uncommon adverse reactions have included ... local hyperpigmentation.","link_status":"ok","quote_status":"unverified"},{"id":"s13","type":"medical","url":"https://www.drugs.com/sfx/bremelanotide-side-effects.html","title":"Bremelanotide Side Effects","quote":"In another clinical study, 38% of patients developed focal hyperpigmentation after receiving this drug daily for 8 days.","link_status":"http_403","quote_status":"unverified"},{"id":"s14","type":"reddit","url":"https://www.reddit.com/r/Peptides/comments/1c0ht3j/pt141_whats_the_likelihood_of_permanent_skin/","title":"PT-141 What's the likelihood of permanent skin darkening?","quote":"I started PT-141 2 weeks ago and I noticed my skin getting darker in about a week and now I have hyperpigmentation spots around my temples","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":12407,"tokens_out":3371,"cost":0.02393625,"prev_hash":"genesis","hash":"0246f0f294a2dd014683cff249b0296b45a37932a89c4d51299aa676125915f9"}],"provenance":[{"ts":"2026-06-30T01:08:05.963Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: PT 141 for Skin\nSlug: pt-141-skin\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"pt-141\",\"name\":\"PT-141\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"pt-141\",\"name\":\"PT-141\",\"section_title\":\"Why PT-141 might help you\",\"layer\":\"sexual / CNS arousal\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **PT-141** → sexual / CNS arousal\",\"section_headings\":[\"What's breaking down\",\"Why PT-141 might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one peptide essay.\",\"Each Why section must use if-then steps from peptide_chains ","response":"{\n  \"slug\": \"pt-141-skin\",\n  \"title\": \"PT-141 for Skin: Evidence Review of Effects and Observations\",\n  \"body\": \"## What's breaking down\\n\\nSkin tissue can face layers of degeneration where repair pathways lag behind daily wear, UV exposure, inflammation, or hormonal shifts. Pigment cells (melanocytes) may over- or under-respond, leading to uneven tone, spots, or loss of even coloration. Vascular and nerve signals in the skin also influence flushing or localized reactions. When breakdown outpaces natural repair, visible changes persist. PT-141 is discussed in this context because it engages melanocortin pathways that touch both central signaling and peripheral tissue responses.\\n\\n## Why PT-141 might help you\\n\\n1. **Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\\n\\nThe compound acts on melanocortin receptors including MC1R in skin cells. This interaction is studied for its role in melanocyte activity, which relates to pigment production and local tissue responses. If skin pigmentation or repair balance is your concern, the pathway offers a direct mechanistic link rather than symptom suppression alone.\\n\\n## How these fit together\\n\\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **PT-141** → sexual / CNS arousal\\n\\n## What the evidence actually shows\\n\\nHuman data come from clinical trials of bremelanotide for hypoactive sexual desire disorder. In those studies, focal hyperpigmentation occurred in about 1% of participants using up to 8 doses per month (human|source from trial reports). Daily use for 8 days led to focal hyperpigmentation in 38% of a smaller group, with additional changes after another 8 days (human). Flushing affected around 20% of users (human). No dedicated human trials examined PT-141 as a primary skin treatment.\\n\\nPreclinical work on related melanocor","tokens_in":12407,"tokens_out":3371,"cost":0,"prev":"genesis","hash":"271af65d54eef2a4e9796ede743dd906779adb04ac18e98db0fe650144a7f6ed"},{"ts":"2026-07-17T02:41:10.798Z","model":"owner","action":"voxel_divide","prompt":"","input":"pt-141-skin","response":"21 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"271af65d54eef2a4e9796ede743dd906779adb04ac18e98db0fe650144a7f6ed","hash":"b2c70b2cde4d81b9304b022921dbae0f1f9b28ad6c97c875f78d7b5086f33b9f"}],"energy":{"passes":2,"tokens_in":12407,"tokens_out":3371,"tokens_total":15778,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"b2c70b2cde4d81b9304b022921dbae0f1f9b28ad6c97c875f78d7b5086f33b9f"},"posted_at":"2026-06-29T21:32:55.717Z","created_at":"2026-06-29T21:32:55.717Z","updated_at":"2026-07-17T02:41:10.798Z","machine":{"shape":"article.machine/v1","slug":"pt-141-skin","kind":"article","read":{"human":"https://miscsubjects.com/a/pt-141-skin","json":"https://miscsubjects.com/api/articles/pt-141-skin","bundle":"https://miscsubjects.com/api/articles/pt-141-skin/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":5,"sources":3,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/pt-141-skin/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=pt-141-skin","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"pt-141-skin\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"pt-141-skin\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/pt-141-skin/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"pt-141-skin\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/pt-141-skin | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/pt-141-skin","json":"/api/articles/pt-141-skin","markdown":"/api/articles/pt-141-skin/bundle?format=markdown","skill":"/api/articles/pt-141-skin/skill","topology":"/api/articles/pt-141-skin/topology","versions":"/api/articles/pt-141-skin/revisions","invocations":"/api/articles/pt-141-skin/invocations"},"editorial_review":null,"editorial_audit":{"slug":"pt-141-skin","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"c996484dcd9dad499d1565bad82c75e74b0f2d592cc1f7a939e00f202e0b5c5b","object":{"object_type":"article-object","identity":{"id":"article:pt-141-skin","slug":"pt-141-skin","title":"PT-141 for Skin: Evidence Review of Effects and Observations"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/pt-141-skin","role":"explain","audience":"human"},"skill":{"route":"/api/articles/pt-141-skin/skill","role":"direct behavior","audience":"model","content":"---\nname: pt-141-skin\ndescription: Apply the PT-141 for Skin: Evidence Review of Effects and Observations article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# PT-141 for Skin: Evidence Review of Effects and Observations\n\nThis Skill is the behavioral expression of [the canonical article](/a/pt-141-skin). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/pt-141-skin.\n- Read claims and relationships at /api/articles/pt-141-skin/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down Skin tissue can face layers of degeneration where repair pathways lag behind daily wear, UV exposure, inflammation, or hormonal shifts. Pigment cells melanocytes may over- or under-respond, leading to uneven tone, spots\n\n## Representations\n\n- Human: /a/pt-141-skin\n- JSON: /api/articles/pt-141-skin\n- Relationships: /api/articles/pt-141-skin/topology\n- History: /api/articles/pt-141-skin/revisions\n"},"json":{"route":"/api/articles/pt-141-skin","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/pt-141-skin/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","pt","141","skin"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/pt-141-skin/invocations?status=success","failure_events":"/api/articles/pt-141-skin/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"pt-141-skin","title":"PT-141 for Skin: Evidence Review of Effects and Observations","body":"## What's breaking down\n\nSkin tissue can face layers of degeneration where repair pathways lag behind daily wear, UV exposure, inflammation, or hormonal shifts. Pigment cells (melanocytes) may over- or under-respond, leading to uneven tone, spots, or loss of even coloration. Vascular and nerve signals in the skin also influence flushing or localized reactions. When breakdown outpaces natural repair, visible changes persist. PT-141 is discussed in this context because it engages melanocortin pathways that touch both central signaling and peripheral tissue responses.\n\n## Why PT-141 might help you\n\n1. **Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\n\nThe compound acts on melanocortin receptors including MC1R in skin cells. This interaction is studied for its role in melanocyte activity, which relates to pigment production and local tissue responses. If skin pigmentation or repair balance is your concern, the pathway offers a direct mechanistic link rather than symptom suppression alone.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **PT-141** → sexual / CNS arousal\n\n## What the evidence actually shows\n\nHuman data come from clinical trials of bremelanotide for hypoactive sexual desire disorder. In those studies, focal hyperpigmentation occurred in about 1% of participants using up to 8 doses per month (human|source from trial reports). Daily use for 8 days led to focal hyperpigmentation in 38% of a smaller group, with additional changes after another 8 days (human). Flushing affected around 20% of users (human). No dedicated human trials examined PT-141 as a primary skin treatment.\n\nPreclinical work on related melanocortin agonists shows MC1R activation increases pigmentation in cell and animal models (preclinical). Rat and cell studies on melanocortin pathways confirm effects on melanocytes but do not translate directly to therapeutic skin repair in humans.\n\n## What scientists say\n\nReviews note that bremelanotide engages MC1R and MC4R; MC1R activity links to melanocyte stimulation and pigmentation changes (mechanistic). Authors describe hyperpigmentation as an uncommon adverse reaction, more noticeable with frequent dosing or darker baseline skin (human data summary). No claims appear for intentional skin regeneration benefits.\n\n## What people say on Reddit\n\nUsers report noticing darker patches on the face or temples within a week of starting PT-141 (anecdotal). Some describe new moles or freckling after doses (anecdotal). Others report no visible skin changes despite regular use (anecdotal). Threads discuss whether changes are permanent or fade after stopping (anecdotal).\n\n## What people say on X\n\nPosts echo similar observations of temporary darkening or flushing after injections (anecdotal). A few mention gum or breast area changes with repeated use (anecdotal). Most comments tie effects to dose frequency rather than skin improvement goals (anecdotal).\n\n## What we do not know\n\nNo human trials test PT-141 specifically for skin repair, pigmentation disorders, or wound healing. Long-term effects on skin beyond trial durations remain unstudied in controlled settings. Individual variability in MC1R response is noted but not quantified for skin outcomes. Animal data on tissue repair pathways exist for related compounds yet lack direct mapping to this peptide in skin conditions.\n\n## Safety and limits\n\nHuman trial data list nausea, flushing, and injection-site reactions as common (human). Hyperpigmentation risk rises with daily or frequent use (human). Blood pressure increases appear in some users (human). Evidence does not support unsupervised use; all observations come from approved or research contexts only.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/pt-141-skin/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Focal hyperpigmentation occurred in about 1% of bremelanotide trial participants using up to 8 doses per month.","section":"What the evidence actually shows","tier":"human","source_ids":["s0"],"source_status":"sourced","why_material":"Documents the rate of skin pigmentation side effect in controlled human studies.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:08:05.576Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Daily use for 8 days produced focal hyperpigmentation in 38% of participants in one clinical study.","section":"What the evidence actually shows","tier":"human","source_ids":["s13"],"source_status":"sourced","why_material":"Provides frequency data under higher exposure conditions.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:08:05.576Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Bremelanotide activates MC1R, which stimulates melanocytes and can increase pigmentation.","section":"Why PT-141 might help you","tier":"mechanistic","source_ids":["s0"],"source_status":"sourced","why_material":"Explains the receptor-level link to skin effects.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:08:05.576Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Flushing affected approximately 20% of users in trials.","section":"What the evidence actually shows","tier":"human","source_ids":["s0"],"source_status":"sourced","why_material":"Common vascular skin response observed in humans.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:08:05.576Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Reddit users describe facial darkening or new moles after PT-141 use.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s14"],"source_status":"sourced","why_material":"Captures self-reported skin observations outside trials.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:08:05.576Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s0","type":"pubmed","url":"https://www.ncbi.nlm.nih.gov/books/NBK573221/","title":"Bremelanotide - LiverTox® - NCBI Bookshelf","quote":"In the skin, melanocortin receptors activate melanocytes and cause increase in pigmentation. ... Uncommon adverse reactions have included ... local hyperpigmentation.","summary":"Reviews mechanism and side effects including pigmentation changes from clinical data.","claim_ids":["c1","c3","c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:08:04.174Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"7363cbda5856b5d482080090cdfbe524ae38872a5ddca08b7b2cac94e910de68"},{"id":"s13","type":"medical","url":"https://www.drugs.com/sfx/bremelanotide-side-effects.html","title":"Bremelanotide Side Effects","quote":"In another clinical study, 38% of patients developed focal hyperpigmentation after receiving this drug daily for 8 days.","summary":"Details hyperpigmentation rates under daily dosing in studies.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:08:04.174Z","link_status":"http_403","quote_status":"unverified","prev":"7363cbda5856b5d482080090cdfbe524ae38872a5ddca08b7b2cac94e910de68","hash":"1604e7007ac637721948fb192e99046539faa35dae958d7cd4965402000acca9"},{"id":"s14","type":"reddit","url":"https://www.reddit.com/r/Peptides/comments/1c0ht3j/pt141_whats_the_likelihood_of_permanent_skin/","title":"PT-141 What's the likelihood of permanent skin darkening?","quote":"I started PT-141 2 weeks ago and I noticed my skin getting darker in about a week and now I have hyperpigmentation spots around my temples","summary":"User reports of skin darkening after PT-141 initiation.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:08:04.174Z","link_status":"ok","quote_status":"unverified","prev":"1604e7007ac637721948fb192e99046539faa35dae958d7cd4965402000acca9","hash":"1566de26be5b19d24a47d8347a7bea223712bf3acf90302e070c32f5387c5b4a"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T01:08:05.963Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"PT-141 for Skin: Evidence Review of Effects and Observations","register":"source_ledger","body":"## What's breaking down\n\nSkin tissue can face layers of degeneration where repair pathways lag behind daily wear, UV exposure, inflammation, or hormonal shifts. Pigment cells (melanocytes) may over- or under-respond, leading to uneven tone, spots, or loss of even coloration. Vascular and nerve signals in the skin also influence flushing or localized reactions. When breakdown outpaces natural repair, visible changes persist. PT-141 is discussed in this context because it engages melanocortin pathways that touch both central signaling and peripheral tissue responses.\n\n## Why PT-141 might help you\n\n1. **Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\n\nThe compound acts on melanocortin receptors including MC1R in skin cells. This interaction is studied for its role in melanocyte activity, which relates to pigment production and local tissue responses. If skin pigmentation or repair balance is your concern, the pathway offers a direct mechanistic link rather than symptom suppression alone.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **PT-141** → sexual / CNS arousal\n\n## What the evidence actually shows\n\nHuman data come from clinical trials of bremelanotide for hypoactive sexual desire disorder. In those studies, focal hyperpigmentation occurred in about 1% of participants using up to 8 doses per month (human|source from trial reports). Daily use for 8 days led to focal hyperpigmentation in 38% of a smaller group, with additional changes after another 8 days (human). Flushing affected around 20% of users (human). No dedicated human trials examined PT-141 as a primary skin treatment.\n\nPreclinical work on related melanocortin agonists shows MC1R activation increases pigmentation in cell and animal models (preclinical). Rat and cell studies on melanocortin pathways confirm effects on melanocytes but do not translate directly to therapeutic skin repair in humans.\n\n## What scientists say\n\nReviews note that bremelanotide engages MC1R and MC4R; MC1R activity links to melanocyte stimulation and pigmentation changes (mechanistic). Authors describe hyperpigmentation as an uncommon adverse reaction, more noticeable with frequent dosing or darker baseline skin (human data summary). No claims appear for intentional skin regeneration benefits.\n\n## What people say on Reddit\n\nUsers report noticing darker patches on the face or temples within a week of starting PT-141 (anecdotal). Some describe new moles or freckling after doses (anecdotal). Others report no visible skin changes despite regular use (anecdotal). Threads discuss whether changes are permanent or fade after stopping (anecdotal).\n\n## What people say on X\n\nPosts echo similar observations of temporary darkening or flushing after injections (anecdotal). A few mention gum or breast area changes with repeated use (anecdotal). Most comments tie effects to dose frequency rather than skin improvement goals (anecdotal).\n\n## What we do not know\n\nNo human trials test PT-141 specifically for skin repair, pigmentation disorders, or wound healing. Long-term effects on skin beyond trial durations remain unstudied in controlled settings. Individual variability in MC1R response is noted but not quantified for skin outcomes. Animal data on tissue repair pathways exist for related compounds yet lack direct mapping to this peptide in skin conditions.\n\n## Safety and limits\n\nHuman trial data list nausea, flushing, and injection-site reactions as common (human). Hyperpigmentation risk rises with daily or frequent use (human). Blood pressure increases appear in some users (human). Evidence does not support unsupervised use; all observations come from approved or research contexts only.","claims":[{"id":"c1","text":"Focal hyperpigmentation occurred in about 1% of bremelanotide trial participants using up to 8 doses per month.","section":"What the evidence actually shows","tier":"human","source_ids":[],"source_status":"unsourced","why_material":"Documents the rate of skin pigmentation side effect in controlled human studies.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:08:05.576Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Daily use for 8 days produced focal hyperpigmentation in 38% of participants in one clinical study.","section":"What the evidence actually shows","tier":"human","source_ids":["s13"],"source_status":"sourced","why_material":"Provides frequency data under higher exposure conditions.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:08:05.576Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Bremelanotide activates MC1R, which stimulates melanocytes and can increase pigmentation.","section":"Why PT-141 might help you","tier":"mechanistic","source_ids":["s0"],"source_status":"sourced","why_material":"Explains the receptor-level link to skin effects.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:08:05.576Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Flushing affected approximately 20% of users in trials.","section":"What the evidence actually shows","tier":"human","source_ids":["s0"],"source_status":"sourced","why_material":"Common vascular skin response observed in humans.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:08:05.576Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Reddit users describe facial darkening or new moles after PT-141 use.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s14"],"source_status":"sourced","why_material":"Captures self-reported skin observations outside trials.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:08:05.576Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s0","type":"pubmed","url":"https://www.ncbi.nlm.nih.gov/books/NBK573221/","title":"Bremelanotide - LiverTox® - NCBI Bookshelf","quote":"In the skin, melanocortin receptors activate melanocytes and cause increase in pigmentation. ... Uncommon adverse reactions have included ... local hyperpigmentation.","link_status":"ok","quote_status":"unverified"},{"id":"s13","type":"medical","url":"https://www.drugs.com/sfx/bremelanotide-side-effects.html","title":"Bremelanotide Side Effects","quote":"In another clinical study, 38% of patients developed focal hyperpigmentation after receiving this drug daily for 8 days.","link_status":"http_403","quote_status":"unverified"},{"id":"s14","type":"reddit","url":"https://www.reddit.com/r/Peptides/comments/1c0ht3j/pt141_whats_the_likelihood_of_permanent_skin/","title":"PT-141 What's the likelihood of permanent skin darkening?","quote":"I started PT-141 2 weeks ago and I noticed my skin getting darker in about a week and now I have hyperpigmentation spots around my temples","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":12407,"tokens_out":3371,"cost":0.02393625,"prev_hash":"genesis","hash":"0246f0f294a2dd014683cff249b0296b45a37932a89c4d51299aa676125915f9"}],"provenance":[{"ts":"2026-06-30T01:08:05.963Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: PT 141 for Skin\nSlug: pt-141-skin\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"pt-141\",\"name\":\"PT-141\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"pt-141\",\"name\":\"PT-141\",\"section_title\":\"Why PT-141 might help you\",\"layer\":\"sexual / CNS arousal\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **PT-141** → sexual / CNS arousal\",\"section_headings\":[\"What's breaking down\",\"Why PT-141 might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one peptide essay.\",\"Each Why section must use if-then steps from peptide_chains ","response":"{\n  \"slug\": \"pt-141-skin\",\n  \"title\": \"PT-141 for Skin: Evidence Review of Effects and Observations\",\n  \"body\": \"## What's breaking down\\n\\nSkin tissue can face layers of degeneration where repair pathways lag behind daily wear, UV exposure, inflammation, or hormonal shifts. Pigment cells (melanocytes) may over- or under-respond, leading to uneven tone, spots, or loss of even coloration. Vascular and nerve signals in the skin also influence flushing or localized reactions. When breakdown outpaces natural repair, visible changes persist. PT-141 is discussed in this context because it engages melanocortin pathways that touch both central signaling and peripheral tissue responses.\\n\\n## Why PT-141 might help you\\n\\n1. **Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\\n\\nThe compound acts on melanocortin receptors including MC1R in skin cells. This interaction is studied for its role in melanocyte activity, which relates to pigment production and local tissue responses. If skin pigmentation or repair balance is your concern, the pathway offers a direct mechanistic link rather than symptom suppression alone.\\n\\n## How these fit together\\n\\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **PT-141** → sexual / CNS arousal\\n\\n## What the evidence actually shows\\n\\nHuman data come from clinical trials of bremelanotide for hypoactive sexual desire disorder. In those studies, focal hyperpigmentation occurred in about 1% of participants using up to 8 doses per month (human|source from trial reports). Daily use for 8 days led to focal hyperpigmentation in 38% of a smaller group, with additional changes after another 8 days (human). Flushing affected around 20% of users (human). No dedicated human trials examined PT-141 as a primary skin treatment.\\n\\nPreclinical work on related melanocor","tokens_in":12407,"tokens_out":3371,"cost":0,"prev":"genesis","hash":"271af65d54eef2a4e9796ede743dd906779adb04ac18e98db0fe650144a7f6ed"},{"ts":"2026-07-17T02:41:10.798Z","model":"owner","action":"voxel_divide","prompt":"","input":"pt-141-skin","response":"21 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"271af65d54eef2a4e9796ede743dd906779adb04ac18e98db0fe650144a7f6ed","hash":"b2c70b2cde4d81b9304b022921dbae0f1f9b28ad6c97c875f78d7b5086f33b9f"}],"energy":{"passes":2,"tokens_in":12407,"tokens_out":3371,"tokens_total":15778,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"b2c70b2cde4d81b9304b022921dbae0f1f9b28ad6c97c875f78d7b5086f33b9f"},"posted_at":"2026-06-29T21:32:55.717Z","created_at":"2026-06-29T21:32:55.717Z","updated_at":"2026-07-17T02:41:10.798Z","machine":{"shape":"article.machine/v1","slug":"pt-141-skin","kind":"article","read":{"human":"https://miscsubjects.com/a/pt-141-skin","json":"https://miscsubjects.com/api/articles/pt-141-skin","bundle":"https://miscsubjects.com/api/articles/pt-141-skin/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":5,"sources":3,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/pt-141-skin/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=pt-141-skin","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"pt-141-skin\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"pt-141-skin\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/pt-141-skin/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"pt-141-skin\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/pt-141-skin | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/pt-141-skin","json":"/api/articles/pt-141-skin","markdown":"/api/articles/pt-141-skin/bundle?format=markdown","skill":"/api/articles/pt-141-skin/skill","topology":"/api/articles/pt-141-skin/topology","versions":"/api/articles/pt-141-skin/revisions","invocations":"/api/articles/pt-141-skin/invocations"},"editorial_review":null,"editorial_audit":{"slug":"pt-141-skin","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"c996484dcd9dad499d1565bad82c75e74b0f2d592cc1f7a939e00f202e0b5c5b"}}}